Adherence and persistence with direct oral anticoagulants by dose regimen: A systematic review
British Journal of Clinical Pharmacology · 2025-04 · 91 (4) · 1096-1113
DOI: 10.1002/bcp.70003 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 16.02.2025. Verfasst von Raúl Quirós López und 2 weiteren Autor:innen. Beteiligte Einrichtung: Network for Research in Chronicity, Primary Care, and Health Prevention and Promotion, Costa del Sol University Hospital, Marbella, Spain. Hauptthemen laut MEDLINE: Atrial Fibrillation, Anticoagulants, Stroke, Factor Xa Inhibitors. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Daiichi Sankyo España.
Abstract (Originalsprache)
Introduction
Direct oral anticoagulants (DOACs) are used in patients with non‐valvular atrial fibrillation (NVAF) to prevent complications such as embolic events. Poor adherence to DOACs increases the risk of these complications. This manuscript reviews the impact of once‐daily (OD) vs twice‐daily (BID) dosing regimens on adherence and persistence to the authorized DOACs (dabigatran, rivaroxaban, apixaban and edoxaban) in patients with NVAF, aiming to provide insights into guide clinical decision‐making.
Methods
A systematic review was performed. First, a bibliographical search was carried out in PubMed, Scopus and the Cochrane Library. Articles that provided quantitative data comparing adherence and/or persistence associated with OD vs BID regimens of DOACs among patients receiving treatment for NVAF were included. Two analyses of adherence and persistence were conducted, one based on the overall outcomes and another, more restricted, to minimize the risk of overestimating results. Additionally, univariate analyses were conducted based on the number of follow‐up days and the DOAC molecule.
Results
Thirty‐nine studies, involving 976 494 patients, were analysed. The OD regimen demonstrated significantly higher adherence and persistence ( P < .05) than the BID regimen in most outcomes. Adherence favoured OD in 53.1% of cases, while only 12.2% favoured BID. Similarly, persistence was higher with the OD regimen in 67.7% of cases compared to 14.9% for the BID regimen. These results remained consistent over time; nevertheless, variations were observed depending on the specific DOAC molecules.
Conclusion
Adherence and persistence of treatment with DOACs in patients with NVAF were greater for the OD than for the BID regimen.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Network for Research in Chronicity, Primary Care, and Health Prevention and Promotion, Costa del Sol University Hospital, Marbella, Spain.
- Geriatric Unit, Internal Medicine Department, Hospital Universitari de Bellvitge, Systemic Diseases and Ageing Group, Cardiovascular, Respiratory, Barcelona, Spain.
- Systemic Diseases and Cellular Aging Program, Institut d'Investigació Biomèdica de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
- Department of Medicine I, Division of Thrombosis & Hemostasis, University Hospital "Carl Gustac Carus", Dresden, Germany.
ORCID-Profile: Raúl Quirós López
Förderung
- Daiichi Sankyo España
Zitieren
APA
Quirós López, R., Formiga Pérez, F., & Beyer-Westendorf, J. (2025). Adherence and persistence with direct oral anticoagulants by dose regimen: A systematic review. British Journal of Clinical Pharmacology, 91(4), 1096-1113. https://doi.org/10.1002/bcp.70003
Vancouver
Quirós López R, Formiga Pérez F, Beyer-Westendorf J. Adherence and persistence with direct oral anticoagulants by dose regimen: A systematic review. British Journal of Clinical Pharmacology. 2025;91(4):1096-1113. doi:10.1002/bcp.70003
BibTeX
@article{QuirsLpez2025,
author = {Quirós López, Raúl and Formiga Pérez, Francesc and Beyer-Westendorf, Jan},
title = {Adherence and persistence with direct oral anticoagulants by dose regimen: A systematic review},
journal = {British Journal of Clinical Pharmacology},
year = {2025},
volume = {91},
number = {4},
pages = {1096--1113},
doi = {10.1002/bcp.70003}
}
EUVIMED